Corient Private Wealth
IDXX icon

Corient Private Wealth’s Idexx Laboratories IDXX Stock Holding History

Corient Private Wealth’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.5M Sell
122,006
-177,206
-59% -$114M 0.1% 189
2025
Q4 		$155M Buy
299,212
+183,035
+158% +$125M 0.1% 187
2025
Q3 		$74.2M Sell
116,177
-1,297
-1% -$787K 0.12% 178
2025
Q2 		$63M Sell
117,474
-3,030
-3% -$1.45M 0.08% 202
2025
Q1 		$50.6M Sell
120,504
-4,946
-4% -$2.15M 0.08% 219
2024
Q4 		$51.9M Sell
125,450
-180,904
-59% -$79.3M 0.09% 221
2024
Q3 		$155M Buy
306,354
+157,692
+106% +$76.6M 0.24% 95
2024
Q2 		$72.4M Buy
148,662
+678
+0.5% +$340K 0.13% 167
2024
Q1 		$79.9M Buy
147,984
+5,389
+4% +$2.95M 0.14% 158
2023
Q4 		$79.1M Buy
142,595
+10,125
+8% +$4.75M 0.15% 154
2023
Q3 		$57.9M Buy
132,470
+4,224
+3% +$2.11M 0.13% 168
2023
Q2 		$64.4M Sell
128,246
-3,631
-3% -$1.74M 0.15% 152
2023
Q1 		$65.9M Buy
131,877
+107,953
+451% +$51.7M 0.18% 132
2022
Q4 		$9.81M Buy
+23,924
New +$9.29M 0.04% 368

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Corient Private Wealth's IDXX Position: Q1 2026 in Review

Corient Private Wealth reduced its Idexx Laboratories (IDXX) stake by 59% in Q1 2026, selling an estimated $114M and leaving 122,006 shares worth $68.5M. The position accounts for 0.1% of the portfolio, ranked #189.

Corient Private Wealth first reported a position in IDXX in Q4 2022 and has held it in 14 quarters since. The position peaked at $155M in Q4 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Corient Private Wealth held 122,006 shares of Idexx Laboratories worth $68.5M as of Q1 2026.
  • Corient Private Wealth sold 177,206 Idexx Laboratories shares in Q1 2026, an estimated $114M.
  • Idexx Laboratories made up 0.1% of Corient Private Wealth's portfolio in Q1 2026, its #189 holding.
  • Corient Private Wealth first reported a position in Idexx Laboratories in Q4 2022 and has held it in 14 quarters since.
  • Corient Private Wealth's Idexx Laboratories position peaked at $155M in Q4 2025.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.